(R)-5-Acyloxymethyl-and (S)-5-acylaminomethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinones 2a-s were synthesized as pyrrole analogues of toloxatone (Humoryl ® ), an anti-MAO agent used in clinical therapy because of its antidepressant properties. Their ability to inhibit the enzymatic isoforms MAO-A and MAO-B was evaluated. From the data most 2a-s showed high reversibility and selective MAO-A inhibitory activity. They exhibited an inhibitory potency (K iMAO-A ) of 0.16-0.90 µM comparable to that found for toloxatone (K iMAO-A = 0.38 µM), the A isoform being 11-fold more selective. The results indicate that 2a-s show promise as new antidepressant agents.
Introduction
Monoamine oxidase (MAO, EC 1.4.3.4) catalyzes the oxidative deamination of biogenic amines both from exogenous and endogenous sources, such in the central nervous system and in peripheral tissues. This enzyme is a flavoprotein tightly bound to the mitochondrial outer membranes of neuronal, glial and other cells. 1 On the basis of their different amino acid sequences, substrate and inhibitor specificities two subtypes of MAO, termed MAO-A and MAO-B, have been described. Isoform A preferentially oxidases serotonin, adrenaline and norepinephrine, and is selectively inhibited by clorgyline, whereas isoform B mainly catalyses the oxidative deamination of β-phenylethylamine and benzylamine, and is selectively inhibited by L-deprenyl. 2 Both isoenzymes appear to consist of two subunits 3, 4 coded by different genes, and they have a 70% amino acid identity. 5 Each isoenzyme has an FAD moiety covalently linked to a cysteine residue, Cys404 (MAO-A) and Cys397 (MAO-B), through a 8α-cysteinyl-riboflavin. [6] [7] [8] [9] Although the peptide sequences of the two forms present certain differences, the FAD cofactor is linked to the same pentapeptide (Ser-Gly-Gly-Cys-Tyr) whatever the form (A or B) of MAO found in different mammalian tissues. 5 Due to the key role played by the two MAO forms in metabolism of monoamine neurotransmitters and exogenous aryl-alkylamines, these oxidases have long been a pharmacological focus because both reversible and irreversible MAO inhibitors (MAOIs) of both isoforms A and B have been administered clinically in the treatment of several neurological diseases, such as depression, social phobias, obsessive-compulsive disorders, schizophrenia, Parkinson's Disease (PD). In particular, selective MAO-A inhibitors (e.g., clorgyline) 10 are used as antidepressant and antianxiety drugs, and they are claimed to protect neuronal cells against apoptosis, 11 while selective MAO-B inhibitors (e.g., L-deprenil) 12 can be used either alone or in combination with L-DOPA, in the treatment of PD. 13 Elevated levels of the isoform B have also been assayed in plaque-associated astrocytes of brains from Alzheimer's patients, 14 and MAO-B inhibitors are currently in clinical trials for the treatment of this disease.
On one hand, such isoform-selective MAOIs present a favourable tolerability profile, being effective agents in many neuropsychiatric and effective disorders. On the other hand, they suffer from many important limitations to the use (loss of selectivity at high dosages, wide range of MAOI-drug and MAOI-food interactions) as they inhibit the MAO forms in an irreversible manner. 15, 16 During the 1980s new selective, reversible MAOIs appeared, showing higher selectivity over a wide dose range and during chronic use, and inducing minimal adverse side reactions. Among them, 2-oxazolidinone derivatives including toloxatone (Humoryl Recently we disclosed a new series of 3-(1H-pyrrol-1-yl)-2-oxazolidinones 1 bearing a hydroxymethyl, alkoxymethyl, (un)substituted-aminomethyl, or azidomethyl side chain at the C 5 Pursuing the study in this field, we describe in the present paper the synthesis and the biochemical characterization of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinones 2 carrying as substitutions at C 5 position different acyloxymethyl or acylaminomethyl moieties (Figure 1 ).
Results and Discussion
Chemistry 1-(Phenylmethoxycarbonylamino)-1H-pyrrole 3 25 was prepared from benzyl carbazate and 2,5-dimethoxytetrahydrofuran in ethanol/acetic acid medium as the starting material for the synthesis of title derivatives. After treatment with n-butylithium in hexanes at -78 °C , the Biological Evaluation (R)-5-Acyloxymethyl-and (S)-5-acylaminomethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinones 2a-s were evaluated for their ability to inhibit MAO-A and MAO-B, in comparison with toloxatone as reference drug. Bovine brain mitochondria were used as the enzyme source and were isolated according to Basford. 26 Activities of MAO-A and MAO-B were determined by a fluorometric method with kynuramine as a substrate, at several different final concentrations. The K i values (µM) against the two isoenzymatic MAO forms and the A-selectivity (expressed as K iMAO-B /K iMAO-A ratio) are reported in Table 1 . All compound showed inhibitory activity against the A isoform of the MAO enzyme higher than that exerted against MAO-B. Furthermore, all derivatives displayed a reversible mode of action since dialysis for 24 h in a cold room, at 4 °C, against 0.1 M potassium phosphate buffer (pH 7.2) was able to restore from 90 to 100% activity of the native enzyme. Among test derivatives, the majority of them (2a,d,g-k,m,n,p) showed similar MAO-A inhibiting activity to that of toloxatone, they being often (2d,g,h,j,k,m,n,p) more A-selective. Derivative 2c was 2-fold more powerful than toloxatone in our enzyme assay, but 2-fold less selective. With the sole exception of derivative 2c, among ester derivatives 2a-m elongation of the 5-acyloxymethyl chain (2a-e,m) or introduction on phenyl ring of both electron-attractor and -withdrawing groups (2f-l) did not increase the inhibitory activity of compounds. Interestingly, 2b with an aliphatic chain longer by one carbon atom with respect to that of 2a was 88-fold more A-selective than 2a.
No amide derivatives (2o-s) showed higher inhibiting activity than toloxatone; nevertheless, compounds 2o,p,s were more A-selective, with 2p reaching the selectivity value of 364. Replacement of (S)-5-acetylaminomethyl with (S)-5-benzoylaminomethyl substitution gave an improvement of activity as well as A-selectivity, while introduction of phenylacetylaminomethyl moiety at 2-oxazolidinone C 5 position (2q) led to a drastic decrease of selectivity. 
Conclusions

Experimental Section
General Procedures. Melting points were determined on a Büchi 530 melting point apparatus and are uncorrected. Infrared (IR) spectra (KBr) were recorded on a Perkin-Elmer Spectrum One instrument.
1 H NMR spectra were recorded at 200 MHz on a Bruker AC 200 spectrometer; chemical shifts are reported in δ (ppm) units relative to the internal reference tetramethylsilane (Me 4 Si). All compounds were routinely checked by TLC and 1 H NMR. TLC was performed on aluminum-backed silica gel plates (Merck DC-Alufolien Kieselgel 60 F 254 ) with spots visualized by UV light. All solvents were reagent grade and, when necessary, were purified and dried by standards methods. Concentration of solutions after reactions and extractions involved the use of a rotary evaporator operating at a reduced pressure of ca. 20 Torr. Organic solutions were dried over anhydrous sodium sulfate. Analytical results are within ±0.40% of the theoretical values. All chemicals were purchased from Aldrich Chimica, Milan (Italy) or Lancaster Synthesis GmbH, Milan (Italy) and were of the highest purity. Chemical and physical properties of compounds 2,4-7 are reported in Table 2 . 
Synthesis of (R)-5-hydroxymethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinone (4).
To a solution of compound 3 25 (1.0 g, 4.63 mmol) in dry THF (20 mL) at -78 °C under nitrogen atmosphere n-butyllithium (1.6 M in hexanes, 2.3 mL, 3.69 mmol) was added dropwise over a period of 5 min. The reaction mixture was stirred at -78 °C for 1 h, followed by addition of (R)-glycidyl butyrate (0.53 mL, 3.69 mmol). The reaction mixture was stirred initially at -78 °C for 1 h and then at room temperature for 5 h. After, the reaction mixture was quenched by addition of saturated NH 4 Cl solution (100 mL) and then extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with water (100 mL) and brine (100 mL), and dried. The residue obtained upon evaporation of solvent was chromatographed over silica gel and eluted with ethyl acetate to give the alcohol 4 as a white solid. IR (KBr) 3400 (OH), 1760 (NCOO) cm 
Synthesis of (R)-5-methanesulfonyloxymethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinone (5).
To a solution of the alcohol 4 (510 mg, 3 mmol) in dry dichloromethane (15 mL) at 0 °C under nitrogen atmosphere triethylamine (1.04 mL, 7.5 mmol) was added, followed by addition of methanesulfonyl chloride (0.27 mL, 2.1 mmol) over a period of 2 min. The reaction mixture was stirred at 0 °C for 1 h, and then was worked up by adding water (100 mL) followed by extraction with dichloromethane (3 x 50 mL). The combined organic extracts were washed with water (100 mL) and brine (100 mL), and dried. The solvent was evaporated to give the desired methanesulfonate 5 as a gum, which was taken up for the next step without any purification. 
Synthesis of (R)-5-azidomethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinone (6).
To a solution of 5 (600 mg, 2.42 mmol) in dry N,N-dimethylformamide (DMF, 10 mL) under nitrogen atmosphere was added sodium azide (315 mg, 4.84 mmol), and the resulting mixture was stirred at 80 °C for 2 h. The reaction mixture was allowed to cool to room temperature and worked up by addition water (100 mL) followed by extraction with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with water (100 mL) and brine (100 mL), and dried. 
Synthesis of (S)-5-aminomethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinone (7)
. To a solution of 7 (0.96 g, 4.64 mmol) in methanol (80 mL) placed in Parr apparatus palladium on 10% carbon was added, then the mixture was hydrogenated at 50 psi and 25 °C for 1 h. At last, palladium was filtered and methanol was evaporated to afford an oily residue that was chromatographed on silica gel and eluted with chloroform:methanol 9:1 to provide the amine derivative 7. IR 3350-3280 (NH 2 
General procedure for the synthesis of (R)-5-acyloxymethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinones 2a-m
To a solution of the alcohol 4 (1 eq) in dry dichloromethane (50 mL) at 0 °C under nitrogen triethylamine (2.5 eq) was added, followed by addition of the appropriate acyl chloride (1.2 eq) dropwise. The mixture was stirred at room temperature for 1-6 h (TLC control), then it was diluted with dichloromethane (50 mL) and washed with water (2 x 100 mL) followed by brine (100 mL). The organic extract was dried, evaporated, and passed through a column over silica gel eluting with ethyl acetate:chloroform 1:10 to afford the acylated product as a solid. 5-N-methylaminothiocarbonyloxymethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinone  (2n) . To a solution of 4 (0.5 g, 2.75 mmol) in dry tetrahydrofuran (20 mL) sodium hydride (82.5 mg, 2.75 mmol) in mineral oil (80%) was added, and the reaction was stirred for 15 min. Then N-methylisothiocyanate (0.23 mL, 3.3 mmol) was added, and the resulting mixture was stirred while cooling (ice bath). At the complete consumption of starting material (TLC control, 2 days) the reaction was worked. The residue obtained was passed through a column of silica gel eluting with ethyl acetate:chloroform 1:1 to afford the product 2n as a solid. 
(2a). IR (KBr
General procedure for the synthesis of (S)-5-acylaminomethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinones 2o-r
To a solution of 7 (1 eq) in dry dichloromethane (50 mL) at 0 °C under nitrogen triethylamine (2.5 eq) was added, followed by addition of the appropriate acyl chloride (1.2 eq) dropwise. The resulting mixture was stirred at room temperature for 1-6 h (TLC control), then it was diluted with dichloromethane (50 mL) and washed with water (2 x 100 mL) followed by brine (100 mL). The organic extract was dried, evaporated, and chromatographed on silica gel eluting with chloroform:methanol 9:1 to afford the product as a solid. 5-N'-methylthioureidomethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinone (2s) . To a solution of 7 (0.5 g, 2.76 mmol) in dry tetrahydrofuran (20 mL) N-methylisothiocyanate
Synthesis of (S)-
